| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided (used) by investing activities | 51,728 | 39,700 |
| Proceeds from the exercise of stock options and common stock issued under the 2020 eip | 113 | 113 |
| Net cash provided by financing activities | 113 | 113 |
| Impact of exchange rates on cash, cash equivalents, and restricted cash | 8 | 6 |
| Net increase (decrease) in cash and cash equivalents | -4,539 | 3,251 |
| Cash and cash equivalents at beginning of period | 40,876 | - |
| Cash and cash equivalents at end of period | 36,337 | - |
PMV Pharmaceuticals, Inc. (PMVP)
PMV Pharmaceuticals, Inc. (PMVP)